CA3063938A1 - Compounds, compositions and methods - Google Patents

Compounds, compositions and methods Download PDF

Info

Publication number
CA3063938A1
CA3063938A1 CA3063938A CA3063938A CA3063938A1 CA 3063938 A1 CA3063938 A1 CA 3063938A1 CA 3063938 A CA3063938 A CA 3063938A CA 3063938 A CA3063938 A CA 3063938A CA 3063938 A1 CA3063938 A1 CA 3063938A1
Authority
CA
Canada
Prior art keywords
optionally substituted
compound
alkyl
disease
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3063938A
Other languages
English (en)
French (fr)
Inventor
Giorgio Bonanomi
Anthony A. ESTRADA
Jianwen A. FENG
Brian Fox
Cinzia Maria FRANCINI
Cheng Hu
Colin Philip Leslie
Maksim OSIPOV
Anantha Sudhakar
Zachary K. Sweeney
Javier De Vicente Fidalgo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Denali Therapeutics Inc
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of CA3063938A1 publication Critical patent/CA3063938A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CA3063938A 2017-05-17 2018-05-17 Compounds, compositions and methods Pending CA3063938A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762507682P 2017-05-17 2017-05-17
US62/507,682 2017-05-17
PCT/US2018/033269 WO2018213634A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Publications (1)

Publication Number Publication Date
CA3063938A1 true CA3063938A1 (en) 2018-11-22

Family

ID=64274734

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3063938A Pending CA3063938A1 (en) 2017-05-17 2018-05-17 Compounds, compositions and methods

Country Status (11)

Country Link
US (2) US11174262B2 (enExample)
EP (1) EP3625234B1 (enExample)
JP (2) JP7140781B2 (enExample)
KR (1) KR102637541B1 (enExample)
CN (1) CN110914275A (enExample)
AU (2) AU2018269745C1 (enExample)
BR (1) BR112019023979A2 (enExample)
CA (1) CA3063938A1 (enExample)
IL (1) IL270505B2 (enExample)
MX (1) MX2019013642A (enExample)
WO (1) WO2018213634A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3552017T (lt) * 2016-12-09 2022-05-10 Denali Therapeutics Inc. Junginiai, naudotini kaip ripk1 inhibitoriai
CA3063938A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods
PL3984523T3 (pl) 2018-12-07 2026-02-02 Neurocrine Biosciences, Inc. Antagonista receptora crf1, jego formulacje farmaceutyczne i postacie stałe do leczenia wrodzonego przerostu nadnerczy
ES3039926T3 (en) 2019-12-04 2025-10-27 Neurocrine Biosciences Inc Crf receptor antagonists and methods of use
US20240024330A1 (en) * 2020-08-26 2024-01-25 Neurocrine Biosciences, Inc. Crf receptor antagonists and methods of use
US20240425524A1 (en) * 2021-10-27 2024-12-26 Merck Sharp & Dohme Llc Spirotricycle ripk1 inhibitors and methods of uses thereof
CN121986105A (zh) * 2023-08-31 2026-05-05 杭州百诚医药科技股份有限公司 苯并氮杂䓬酮类化合物及其用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4290952A (en) * 1980-06-23 1981-09-22 American Home Products Corporation Aryl-1-mercaptoalkanoylproline and homoproline derivatives
US4320057A (en) * 1980-06-23 1982-03-16 American Home Products Corporation Aryl--pyrrolo--thiazepin--diones and aryl--piperidino--thiazepin--diones
BRPI0506883A (pt) * 2004-01-16 2007-05-29 Univ Michigan miméticos de smac conformacionalmente comprimidos e seus usos
BRPI0513310A (pt) * 2004-07-12 2008-05-06 Idun Pharmaceuticals Inc análogos de tetrapeptìdeo
AU2006255084A1 (en) * 2005-06-08 2006-12-14 Novartis Ag Organic compounds
TWI370130B (en) * 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
MX2009000824A (es) 2006-07-24 2009-02-04 Tetralogic Pharmaceuticals Cor Antagonistas dimericos de las proteinas inhibidoras de la apoptosis.
WO2014066435A1 (en) 2012-10-22 2014-05-01 City Of Hope Etp derivatives
US20150023913A1 (en) * 2013-07-02 2015-01-22 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2016094846A1 (en) 2014-12-11 2016-06-16 President And Fellows Of Harvard College Inhibitors of cellular necrosis and related methods
WO2016101887A1 (en) * 2014-12-24 2016-06-30 National Institute Of Biological Sciences, Beijing Necrosis inhibitors
CA3063938A1 (en) * 2017-05-17 2018-11-22 Denali Therapeutics Inc. Compounds, compositions and methods

Also Published As

Publication number Publication date
EP3625234A4 (en) 2021-03-10
EP3625234A1 (en) 2020-03-25
JP2022174180A (ja) 2022-11-22
AU2018269745B2 (en) 2022-01-27
AU2018269745A1 (en) 2019-11-28
IL270505B2 (en) 2023-09-01
AU2022202524A1 (en) 2022-05-12
US11851433B2 (en) 2023-12-26
US20220024938A1 (en) 2022-01-27
AU2018269745C1 (en) 2022-06-09
EP3625234B1 (en) 2023-09-20
KR20200006120A (ko) 2020-01-17
MX2019013642A (es) 2020-07-20
KR102637541B1 (ko) 2024-02-15
JP2020520925A (ja) 2020-07-16
US20200079784A1 (en) 2020-03-12
AU2022202524B2 (en) 2023-10-05
WO2018213634A1 (en) 2018-11-22
US11174262B2 (en) 2021-11-16
IL270505B1 (en) 2023-05-01
BR112019023979A2 (pt) 2020-06-09
IL270505A (enExample) 2019-12-31
CN110914275A (zh) 2020-03-24
JP7140781B2 (ja) 2022-09-21

Similar Documents

Publication Publication Date Title
AU2022202524B2 (en) Compounds, compositions and methods
US10709692B2 (en) Isoxazolidine derived inhibitors of receptor interacting protein kinase 1 (RIPK1)
US12180211B2 (en) Compounds, compositions and methods
AU2018346597B2 (en) Inhibiting Ubiquitin Specific Peptidase 30
CA3071024A1 (en) Compounds, compositions and methods
EP3624797A1 (en) Kinase inhibitors and uses thereof
CA3012832A1 (en) N-azepinyl-carboxamide inhibitors of receptor-interacting protein kinase1
JP2021524440A (ja) ユビキチン特異的ペプチダーゼ３０（ｕｓｐ３０）阻害剤として有用な縮合二環化合物
CA2970525A1 (en) Inhibitors of cellular necrosis and related methods
HK40016450B (en) Compounds useful as ripk1 inhibitors
WO2025260014A1 (en) Compounds, compositions, and methods
OA19864A (en) Compounds, compositions, and methods.
EA052777B1 (ru) Пиримидин-2-иламино-1н-пиразолы в качестве ингибиторов lrrk2 для применения при лечении нейродегенеративных заболеваний

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220915

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240821

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250211

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250613

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250613

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251106

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260106

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260630